← Leaderboards
Vivian A Fonseca
Tulane University Of Louisiana
$5,822,487
Attributed
$6,094,197
Total exposure
27
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,094,197 · 27
By mechanism
U54$5,062,859 · 2
R01$543,421 · 1
M01$487,917 · 24
Top collaborators
- James M Hempe2 shared
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Jiang He$53,644,406
- Luis Gabriel Navar$15,722,322
- Lee Hamm$10,754,844
- Lu Qi$19,868,722
- Kailash N Pandey$11,062,222
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationNoninsulin Dependent Diabetes MellitusDiabetes Mellitus TherapyPatient Oriented ResearchDiabetes MellitusCardiovascular DiseasesReportingVascular EndotheliumCenter For Translational Science ActivitiesBiobankAdvertisingBiomarkerAlabamaCollaborationsClinical Trial EnrollmentCareerClinical DevelopmentCommunitiesClinical SciencesCardiovascular FunctionAldehyde ReductaseCareer Development
Grant awards (41)
Core 01: Professional Development Core$1,524,740
U54 · FY2025 · GM · contact PI
Core 01: Professional Development Core$1,202,453
U54 · FY2024 · GM · contact PI
Core 01: Professional Development Core$1,217,094
U54 · FY2023 · GM · contact PI
Core 01: Professional Development Core$1,118,572
U54 · FY2022 · GM · contact PI
Biological Variation in A1c on Mortality, Cardiovascular Events, Hypoglycemia$237,837
R01 · FY2012 · HL
Impact of Biological Variation in A1c on Mortality, Cardiovascular Events, and Hy$305,584
R01 · FY2011 · HL
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD) TRIAL$165,527
M01 · FY2006 · RR · contact PI
INSULIN ASPART (NOVOLOG) AND LISPRO (HUMALOG) IN INSULIN PUMPS$9,908
M01 · FY2006 · RR · contact PI
TRIAL TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS OF GLUCAGON IN TYPE I$6,411
M01 · FY2006 · RR · contact PI
THE EFFECT OF CARVEDILOL AND METOPROLOL ON PROTEINURIA AND ENDOTHELIAL FUNCTION$5,246
M01 · FY2006 · RR · contact PI
FOREARM ENDOTHELIAL FUNCTION IN NON-INSULIN DEPENDENT DIABETIC PATIENTS$2,720
M01 · FY2006 · RR · contact PI
PLASMA FREE AND TOTAL HOMOCYSTEINE FOLLOWING AN ORAL METHIONINE LOAD$1,749
M01 · FY2006 · RR · contact PI
THE EFFECT OF CHRONIC SILDENAFIL ADMINISTRATION ON BIOCHEMICAL MARKERS$194
M01 · FY2006 · RR · contact PI
STUDY OF LONG-TERM ADMINISTRATION OF NATEGLINIDE AND VALSARTAN$194
M01 · FY2006 · RR · contact PI
TREATMENT OF MYOCARDIAL ISCHEMIA IN ASYMPTOMATIC PATIENTS WITH DIABETES$194
M01 · FY2006 · RR · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD) TRIAL$124,538
M01 · FY2005 · RR
THE EFFECT OF CARVEDILOL AND METOPROLOL ON PROTEINURIA AND ENDOTHELIAL FUNCTION$9,762
M01 · FY2005 · RR
A COMPARISON OF HUMALOG MIX 75/25 WITH HUMULIN 70/30 IN INSULIN REQUIRING DM$6,212
M01 · FY2005 · RR
THE EFFECT OF CHRONIC SILDENAFIL ADMINISTRATION ON BIOCHEMICAL MARKERS$5,029
M01 · FY2005 · RR
DETECTION AND TREATMENT OF MYOCARDIAL ISCHEMIA IN ASYMPTOMATIC DIABETIC PATIENTS$4,437
M01 · FY2005 · RR
FOREARM ENDOTHELIAL FUNCTION IN NON-INSULIN DEPENDENT DIABETIC PATIENTS$4,289
M01 · FY2005 · RR
EFFECT OF PIOGLITAZONE (ACTOS) ON ENDOTHELIAL FUNCTION, INFLAMMATION AND PLASMA$3,698
M01 · FY2005 · RR
TRIAL TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS OF GLUCAGON IN TYPE I$148
M01 · FY2005 · RR
STUDY TO EVALUATE THE EFFECT OF PRE-TREATMENT WITH A DAILY DOSE OF VIAGRA AND DM$148
M01 · FY2005 · RR
PLASMA FREE AND TOTAL HOMOCYSTEINE FOLLOWING AN ORAL METHIONINE LOAD$148
M01 · FY2005 · RR
Action to Control Cardiovascular Risk in Diabetes ACCORD$63,093
M01 · FY2004 · RR
The Effect of Carvedilol and Metoprolol on Proteinuria$15,022
M01 · FY2004 · RR
Study to Evaluate the Effect of Pre-Treatment w/ Viagra$14,492
M01 · FY2004 · RR
Effect of Chronic Sildenafil Administration on Biomarker$10,427
M01 · FY2004 · RR
A Comparison of Humalog Mix 75/25 With Humulin 70/30$8,129
M01 · FY2004 · RR
Detection and Treatment of Myocardial Ischemia$7,599
M01 · FY2004 · RR
Effect of Pioglitazone (ACTOS) on Endothelial Function$3,181
M01 · FY2004 · RR
Long-Term Administration of Nateglinide and Valsartan$1,944
M01 · FY2004 · RR
FOREARM ENDOTHELIAL FUNCTION IN NON-INSULIN DEPENDENT DM$1,414
M01 · FY2004 · RR
Trial to Evaluate the Effect of Starlix on Endothelium$884
M01 · FY2004 · RR
ORAL ZOPOLRESTAT IN DIABETIC POLYNEUROPATHY$0
M01 · FY2001 · RR
ZENARESTAT IN DIABETIC NEUROPATHY$0
M01 · FY2001 · RR
DETERMINE EFFECTS OF DOSES OF METFORMIN IN PATIENTS W/ TYPE 2 DIABETE$0
M01 · FY2001 · RR
DETERMINE EFFECTS OF DOSES OF METFORMIN IN PATIENTS W/ TYPE 2 DIABETE$11,180
M01 · FY2000 · RR
ZENARESTAT IN DIABETIC NEUROPATHY$0
M01 · FY2000 · RR
ORAL ZOPOLRESTAT IN DIABETIC POLYNEUROPATHY$0
M01 · FY2000 · RR